Polymer Technology Systems Inc., a small Indianapolis-based maker of handheld blood monitors, has gone to court to fight
a competitor more than 100 times its size: Roche Diagnostics Corp.
Indianapolis-based Dow AgroSciences LLC has sued Cooper Industries Plc in an effort to clarify its rights to make a canola-based
fluid used in electrical transformers.
Hidden Toilet Paper, a small business in Fishers, patented a device that installs toilet-paper rolls into walls, keeping paper
safe from pets and children.
A federal appeals court will decide whether Eli Lilly and Co. must pay $65.2 million in damages, plus royalties, over a drug-patent
claim.
A decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.’s Evista marks a major
victory for the company, says an analyst who closely follows the pharmaceutical industry.
A panel of five leaders of the state’s life sciences
industry took on a wide range of topics
July 24 at IBJ’s Power Breakfast
at the Westin Indianapolis.
Compared with some of his pharmaceutical CEO peers these days, John Lechleiter has his company on a diet. Instead of using a mega-merger to bulk up before the famine that patent expirations will bring on the industry next year,
Lechleiter has Eli Lilly and Co. burning management fat while looking for smaller companies to munch on.
Eli Lilly & Co. executives are making many trips to Washington to argue for 14 years of sales exclusivity for new drugs made
from cells.
Lawyers holding doctorates in biotech, biology, chemistry and computer sciences are in high demand by firms with strong intellectual
property practices.
Four Indiana businesses have joined more than 100 major companies in an open letter to President Barack Obama, outlining what
they believe are weaknesses of patent reform legislation now before Congress and voicing concern about its potential economic
impact.
John Erlandson, 63, of Lebanon, holds the patent on a recycled-rubber pencil,
which Staples plans to start selling in June.
Eli Lilly & Co. has filed lawsuits against seven generic drug companies in federal court in Indianapolis, asking a judge to
declare its Cymbalta patent valid and to tell the generic companies to back off.
Eli Lilly and Co.’s loss in May of a patent-infringement lawsuit brought by Ariad Pharmaceuticals
Inc. went down as the 6th-largest such jury award last year, a Bloomberg analysis shows.
